| 1,056 | 1 | 996 |
| 下载次数 | 被引频次 | 阅读次数 |
根据脂质代谢稳态失衡与肺癌免疫抑制微环境的形成存在密切关联，结合临床实践，提出“脂浊酿毒”是肺癌转移的重要病机。认为脂毒兼具“脂浊黏滞”与“毒邪攻窜”的特性，其产生的关键在于脾虚运化转输失司，津液不归正化，黏稠者化为脂浊。脂浊停聚，壅塞三焦，郁久化热，蕴结成毒，入络损脏，导致邪毒传舍。并针对性提出健脾助运、消脂解毒、疏利三焦的治法，旨在从调节脂质代谢稳态失衡重塑免疫抑制微环境，以期为中医药防治肺癌转移提供思路。
Abstract：Based on the close association between the imbalance of lipid metabolism homeostasis and the formation of the lung cancer immunesuppressive microenvironment, and combing with the clinical practice, this article proposes that "lipid turbidity generating toxicity" constitutes an important pathomechanism underlying lung cancer metastasis. It is believed that lipid turbidity has the dual characteristics of lipid turbidity and stickiness as well as pathogenic toxins invading and wandering. The key lies in the dysfunction of spleen's transformation and transportation, failing to return body fluids to normal, and the stickiness transforming into lipid turbidity. The accumulation of lipid turbidity blocks the sanjiao （三焦）, causing heat accumulation due to prolonged constraint, which transforms into toxins damaging the meridians and internal organs, leading to the invasion and metastasis of pathogenic toxins. A targeted treatment approach is proposed, which emphasizes fortifying the spleen and promoting transformation, eliminating lipid and resolving toxin, and promoting the flow of the sanjiao. The aim is to regulate the imbalance of lipid metabolism homeostasis to reshape the immunesuppressive microenvironment, with the expectation of guiding clinical practice in preventing and treating lung cancer metastasis with traditional Chinese medicine.
[1]BRAY F,LAVERSANNE M,SUNG H,et al. Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263.
[2]MILLER KD,NOGUEIRA L,MARIOTTO AB,et al. Cancer treatment and survivorship statistics, 2019[J]. CA Cancer J Clin, 2019, 69(5):363-385.
[3]KAO KC,VILBOIS S,TSAI CH,et al. Metabolic communication in the tumour-immune microenvironment[J].Nat Cell Biol, 2022, 24(11):1574-1583.
[4]YANG K,WANG X,SONG C,et al. The role of lipid metabolic reprogramming in tumor microenvironment[J].Theranostics, 2023,13(6):1774-1808.
[5]KITAHARA C,BERRINGTON D,FREEDMAN N,et al.Total cholesterol and cancer risk in a large prospective study in Korea[J]. J Clin Oncol,2011,29(12):1592-1598.
[6]ULMER H,BORENA W,RAPP K,et al. Serum triglyceride concentrations and cancer risk in a large cohort study in Austria[J]. Br J Cancer,2009,101(7):1202-1206.
[7]SHI J,YANG H,DUAN X,et al. Apolipoproteins as differentiating and predictive markers for assessing clinical outcomes in patients with small cell lung cancer[J]. Yonsei Med J,2016,57(3):549-556.
[8]WANG G, QIU M, XING X, et al. Lung cancer scRNAseq and lipidomics reveal aberrant lipid metabolism for early-stage diagnosis[J]. Sci Transl Med,2022,14(630):eabk2756.
[9]李明珠，陈谦峰，陶文娟，等.基于“膏脂”生理特点与病理变化探析慢性代谢性疾病的防治[J].中医杂志，2022,63(4):307-311.
[10]吴深涛.内毒论[J].中医杂志，2017,58(15):1265-1269.
[11]李佃贵.从浊毒理论的建立与应用谈中医学创新与发展[J].中医杂志，2020,61(22):1938-1940.
[12]杨晔，刘悦，张帆，等.基于线粒体研究论脾虚与脏腑疾病的相关性[J].中医杂志，2018,59(20):1742-1746.
[13]DU H, XU T, YU S, et al. Mitochondrial metabolism and cancer therapeutic innovation[J]. Signal Transduct Target Ther, 2025,10(1):245.
[14]MUNIR R,LISEC J,SWINNEN JV,et al. Lipid metabolism in cancer cells under metabolic stress[J]. Br J Cancer,2019,120(12):1090-1098.
[15]CURRIE E,SCHULZE A,ZECHNER R,et al. Cellular fatty acid metabolism and cancer[J]. Cell Metab,2013,18(2):153-161.
[16]张翠翠，秦婷婷，孟昭婷，等.肺癌相关异常脂代谢的研究进展[J].中国癌症杂志，2021, 31(1):76-80.
[17]ZHANG Y,MA K,JIANG L,et al. Revealing the preventable effects of Fu-Zheng-Qu-Xie decoction against recurrence and metastasis of postoperative early-stage lung adenocarcinoma based on network pharmacology coupled with metabolomics analysis[J]. ACS Omega,2023,8(39):35555-35570.
[18]RINGEL AE,DRIJVERS JM,BAKER GJ,et al. Obesity shapes metabolism in the tumor microenvironment to suppress anti-tumor immunity[J]. Cell,2020,183(7):1848-1866.
[19]RAMAN P,DEWITT DL,NAIR MG. Lipid peroxidation and cyclooxygenase enzyme inhibitory activities of acidic aqueous extracts of some dietary supplements[J]. Phytother Res,2008,22(2):204-212.
[20]邹飞雁，邓仲端，瞿智玲，等.脂质过氧化损伤诱导培养的人脐静脉内皮细胞表达细胞间粘附分子1[J].中国动脉硬化杂志，2002,10(2):109-111.
[21]PARK SY,JEONG KJ,PANUPINTHU N,et al. Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9expression[J]. Oncogene,2011,30(11):1351-1359.
[22]DUTTA S,WANG FQ,WU HS,et al. The NF-κB pathway mediates lysophosphatidic acid(LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer(EOC)[J]. Gynecol Oncol,2011,123(1):129-137.
[23]高梦丹，叶旭雪，卢立淮，等.鞘氨醇-1-磷酸受体-1促进肿瘤转移与放疗抵抗的研究进展[J].中华放射医学与防护杂志，2019,39(8):599-602.
[24]于建春，曹晓君，刘云鹤，等.近十年三焦理论研究概述[J].中医杂志，2017,58(19):1621-1623,1628.
[25]吴敏，黄敏娜，刘云鹤，等.贾英杰从三焦“黜浊培本”辨治肺癌经验[J].中华中医药杂志，2023,38(2):683-686.
[26]田建辉，罗斌，阙祖俊，等.癌症转移亚临床阶段核心病机“正虚伏毒”学说[J].上海中医药杂志，2021,55(10):1-3,13.
[27]刘小发.李佃贵：化浊解毒，运脾快胃[N].中国中医药报，2018-05-04(004).
[28]KEWANG L,WEI Y,MEIYE L,et al. The inhibitory effects of modified HSJZ decoction on NSCLC by regulating regulatory T cells via downregulation of EZH2 and PI3K/AKT pathway[J]. J Ethnopharmacol,2025,348:119802.doi:10. 1016/j. jep. 2025. 119802.
[29]ZHAO W,LIU Z,ZHANG Z,et al. Si Jun Zi decoction inhibits the growth of lung cancer by reducing the expression of PD-L1 through TLR4/MyD88/NF-κB pathway[J].J Ethnopharmacol,2024,318(Pt A):116948.
[30]甄毕贤，贾连群，杨关林.四君子汤治疗脾气虚证大鼠的血清代谢物谱群特征研究[J].中华中医药杂志，2017,32(3):1234-1237.
[31]张博.扶正祛邪方调控肺腺癌患者脂质代谢的临床及机制研究[D].上海：上海中医药大学，2021.
[32]QIAN Y,HUANG R,LI S,et al. Ginsenoside Rh2 reverses cyclophosphamide-induced immune deficiency by regulating fatty acid metabolism[J]. J Leukoc Biol,2019,106(5):1089-1100.
[33]QI YS,XIAO MY,XIE P,et al. Comprehensive serum metabolomics and network analysis to reveal the mechanism of gypenosides in treating lung cancer and enhancing the pharmacological effects of cisplatin[J]. Front Pharmacol,2022,13:1070948. doi:10. 3389/fphar.2022. 1070948.
[34]谭先胜，李锴男，苗亚军.绞股蓝皂苷通过上调sTim-3/Tim-3比率抑制非小细胞肺癌细胞免疫逃逸因子的表达[J].免疫学杂志，2021,37(6):520-527.
[35]李艳彦，梁琦.《血证论》水血相因思想初探[J].中医杂志，2015,56(9):731-733.
[36]卢德赵，林韬琦，王萍儿，等.丹参酮ⅡA对泡沫细胞胆固醇平衡的影响[J].中国动脉硬化杂志，2012,20(5):402-406.
[37]何德全，陈友权，王世祥.丹参酮ⅡA通过NF-κB通路抑制脂多糖诱导人脐静脉血管内皮细胞炎性反应的作用机制[J].中西医结合心脑血管病杂志，2021,19(3):428-432.
[38]吕小华，王会敏，韩红霞，等.猫爪草多糖免疫调节及抗氧化活性研究[J].中国中药杂志，2010,35(14):1862-1865.
[39]金颖，张晓梅，许秋雯，等.基于三焦膜性管道论探讨肺癌复发转移[J].环球中医药，2023,16(9):1826-1828.
[40]朱潇雨，吴喆，高瑞柯，等.基于“三焦者，原气之别使”探究阳虚与恶性肿瘤腹膜转移关系[J].中医杂志，2021,62(2):182-184.
[41]郝立杰，赵烽，高治廷，等.木香倍半萜对血管内皮细胞生长因子的抑制作用[J].天然产物研究与开发，2010,22(4):687-691.
[42]章方珺.香附超临界CO2提取物体外抗肿瘤作用的研究[D].杭州：浙江工业大学，2016.
[43]何信用，王群，刘璐，等.基于中药整合药理学平台的苓桂术甘汤治疗脂质代谢紊乱作用机制[J].中华中医药学刊，2020,38(3):183-187,274.
[44]原茵，吴紫璇，郭亚萍，等.基于网络药理学与分子对接探讨五苓散治疗脂代谢疾病的作用机制[J].中药新药与临床药理，2022,33(6):794-803.
[45]袁逸帆，朱睿，龚亚斌，等.苓桂术甘汤加减内服联合消水贴外敷治疗肺癌合并胸腔积液的临床研究[J].上海中医药杂志，2022,56(2):45-48,74.
基本信息:
DOI：10.13288/j.11-2166/r.2025.19.005
中图分类号:R273
引用信息:
[1]王宇立,方媛,周孜奕,等.基于“脂浊酿毒”探讨肺癌转移病机及防治[J].中医杂志,2025,66(19):1989-1994.DOI:10.13288/j.11-2166/r.2025.19.005.
基金信息:
国家自然科学基金(82204842); 上海市科学技术委员会科技计划项目(22YF1445400); 上海医学创新发展基金会科技发展项目(WL-QNRC-2022003K)
2025-09-28
2025-09-28